A recent study has revealed that Metformin, a widely used medication for type 2 diabetes, directly influences brain function in patients. This discovery sheds new light on the drug’s mechanisms beyond its traditional role in lowering blood sugar levels.
Metformin has been a cornerstone in diabetes treatment for over six decades. However, researchers have now decoded its effects on the brain, raising important considerations for type 2 diabetes patients. The study emphasizes the potential for developing alternative therapies that could provide more precise and effective management of diabetes.
The research centers on a protein called Rap1, located in the ventromedial hypothalamus (VMH) region of the brain. Previous studies had linked Rap1 to glucose metabolism, prompting further investigation into its role in diabetes treatment. The findings were published in the journal Science Advances.
Scientists conducted experiments on genetically modified mice lacking Rap1 in the VMH. These mice were fed a high-fat diet to simulate type 2 diabetes conditions. When administered low doses of Metformin orally, the mice showed minimal improvement in blood sugar control. In contrast, other diabetes medications such as insulin and GLP-1 agonists proved effective.
In a significant development, researchers injected minute amounts of Metformin directly into the brains of diabetic mice. This approach resulted in a marked decrease in blood sugar levels, despite the doses being thousands of times lower than typical oral amounts.
Makoto Fukuda, a pathophysiologist at Baylor, explained the rationale behind the study: “It has been widely accepted that Metformin lowers blood glucose mainly by reducing glucose production in the liver, and some studies have suggested action through the gut. We explored the brain’s role because it is a key regulator of whole-body glucose metabolism. Our goal was to determine if and how the brain contributes to Metformin’s anti-diabetic effects.”
The research team also identified the specific neurons affected by Metformin, opening the door for future treatments that could precisely target these brain cells to improve diabetes management.
